ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
INNOSUISSE
Projektnummer
9959.1;5 PFLS-LS
Projekttitel
Novel feeder cell-free and animal product-free culture conditions for therapeutic use of human embryonic stem cells.
Projekttitel Englisch
Novel feeder cell-free and animal product-free culture conditions for therapeutic use of human embryonic stem cells.

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Kurzbeschreibung
Anzeigen
-
-
Anzeigen
Abstract
Anzeigen
-
-
Anzeigen

Erfasste Texte


KategorieText
Kurzbeschreibung
(Deutsch)
Novel feeder cell-free and animal product-free culture conditions for therapeutic use of human embryonic stem cells.
Kurzbeschreibung
(Englisch)
Novel feeder cell-free and animal product-free culture conditions for therapeutic use of human embryonic stem cells.
Abstract
(Deutsch)
Human embryonic stem cells (hESC) hold the potential to cure many critical human diseases. However to date, the successful methods to expand these cells whilst retaining their pluripotency depends on animal-derived additives such as serum or their animal-derived substitutes, and the use of fibroblast feeder cells. Proposing a conceptually novel signalling-based approach, this project aims to develop an entirely novel, fully defined culture method which does not depend on serum or feeders, supports long-term growth and pluripotency of hESC cells and thus is ideally suited to GMP manufacture of cells for therapeutic applications.
Abstract
(Englisch)
Human embryonic stem cells (hESC) hold the potential to cure many critical human diseases. However to date, the successful methods to expand these cells whilst retaining their pluripotency depends on animal-derived additives such as serum or their animal-derived substitutes, and the use of fibroblast feeder cells. Proposing a conceptually novel signalling-based approach, this project aims to develop an entirely novel, fully defined culture method which does not depend on serum or feeders, supports long-term growth and pluripotency of hESC cells and thus is ideally suited to GMP manufacture of cells for therapeutic applications.